Complix to Present at Upcoming BioEquity Europe 2013: http://t.co/jzPUX0k7Bp
posted
FlandersBio informs you about important regional and national life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.
Complix, a biopharmaceutical company focused on the discovery and development of Alphabodies™, a unique class of protein therapeutics that are active against intracellular disease targets, announces that its CEO Dr Mark Vaeck will present at BioEquity Europe 2013 in Stockholm, Sweden (May 22nd-23rd). Details of the presentation are listed below. read more
Galapagos NV (Euronext: GLPG) announced today that its Board of Directors created 648,490 warrants under a new warrant plan for the benefit of employees, directors and independent consultants of the Company and its subsidiaries. read more
Galapagos NV (Euronext: GLPG) announced today that the operational and financial results achieved thus far in 2013 encourage the Company to retain full year 2013 Group revenues guidance of €160 million. read more
ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic and oncology medicines, today issued a business and financial update ending 30 April, 2013. read more
Ablynx [Euronext Brussels: ABLX], the Belgian-based biopharmaceutical company focused on the discovery and development of Nanobodies® for the treatment of serious diseases, today announced its business update for the three-month period ending 31st March 2013. read more
